Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines

Type Article
Date 2021-03
Language English
Author(s) Muñoz-Garcia Javier1, Mazza Mattia2, 3, Alliot Cyrille2, 4, Sinquin CorinneORCID5, Colliec-Jouault SylviaORCID5, Heymann DominiqueORCID1, 6, Huclier-Markai SandrineORCID2, 3
Affiliation(s) 1 : Institut de Cancérologie de l’Ouest, Université de Nantes, Blvd Jacques Monod, F-44805 Saint-Herblain, France
2 : GIP ARRONAX, 1 rue Aronnax, CEDEX 3, F-44817 Nantes, France
3 : Laboratoire SUBATECH, 4 rue Alfred Kastler, BP 20722, CEDEX 3, F-44307 Nantes, France
4 : Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM, U892, 8 quai Moncousu, CEDEX 1, F-44007 Nantes, France
5 : IFREMER, Institut Français de Recherche pour L’exploitation de la mer, rue de l’Ile d’Yeu, BP21105, CEDEX 3, F-44311 Nantes, France
6 : Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield S10 2TN, UK
Source Marine Drugs (1660-3397) (MDPI AG), 2021-03 , Vol. 19 , N. 3 , P. 174 (21p.)
DOI 10.3390/md19030174
WOS© Times Cited 4
Note This article belongs to the Special Issue Marine Carbohydrate-Based Compounds with Medicinal Properties
Keyword(s) exopolysaccharides, scandium, theranostic, cancer cell lines, proliferation

Antimetastatic properties on both murine and human osteosarcoma cell lines (POS-1 and KHOS) have been evidenced using exopolysaccharide (EPS) derivatives, produced by Alteromonas infernus bacterium. These derivatives had no significant effect on the cell cycle neither a pro-apoptotic effect on osteosarcoma cells. Based on this observation, these EPSs could be employed as new drug delivery systems for therapeutic uses. A theranostic approach, i.e., combination of a predictive biomarker with a therapeutic agent, has been developed notably by combining with true pair of theranostic radionuclides, such as scandium 47Sc/44Sc. However, it is crucial to ensure that, once complexation is done, the biological properties of the vector remain intact, allowing the molecular tropism of the ligand to recognize its molecular target. It is important to assess if the biological properties of EPS evidenced on osteosarcoma cell lines remain when scandium is complexed to the polymers and can be extended to other cancer cell types. Scandium-EPS complexes were thus tested in vitro on human cell lines: MNNG/HOS osteosarcoma, A375 melanoma, A549 lung adenocarcinoma, U251 glioma, MDA231 breast cancer, and Caco2 colon cancer cells. An xCELLigence Real Cell Time Analysis (RTCA) technology assay was used to monitor for 160 h, the proliferation kinetics of the different cell lines. The tested complexes exhibited an anti-proliferative effect, this effect was more effective compared to EPS alone. This increase of the antiproliferative properties was explained by a change in conformation of EPS complexes due to their polyelectrolyte nature that was induced by complexation. Alterations of both growth factor-receptor signaling, and transmembrane protein interactions could be the principal cause of the antiproliferative effect. These results are very promising and reveal that EPS can be coupled to scandium for improving its biological effects and also suggesting that no major structural modification occurs on the ligand

Full Text
File Pages Size Access
Publisher's official version 21 811 KB Open access
Top of the page

How to cite 

Muñoz-Garcia Javier, Mazza Mattia, Alliot Cyrille, Sinquin Corinne, Colliec-Jouault Sylvia, Heymann Dominique, Huclier-Markai Sandrine (2021). Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines. Marine Drugs, 19(3), 174 (21p.). Publisher's official version : , Open Access version :